BIO-Europe Spring Presenting Companies 2023
Enveda’s novel drug discovery platform uses metabolomics and machine learning to identify new compounds with distinct properties that overcome key challenges with small molecules. Nature’s chemistry has evolved under billions of years of selective pressure to modulate life’s fundamental phenomena. This has led to incredible diversity of chemical properties and biological activity which is uncharacteristic of traditional small molecule libraries and inaccessible to even cutting-edge library generation technologies. We’re harnessing this untapped potential to rapidly deliver new medicines, and hope, for complex diseases. Our chemistry provides a unique opportunity to access known and emerging modalities of tuning biology. We are rapidly identifying novel chemistry that degrades or stabilizes proteins by acting like a molecular glue, changes the shape of difficult-to-drug proteins allowing modulation of a previously undruggable targets. In three years since inception, Enveda's platform has translated to highly differentiated pipeline assets across a number of important targets and pathways, including cytokine-receptor interactions, GPCRs, and the inflammasome pathway. Our emerging pipeline includes novel compounds that modulate the inflammasome pathway; non-opioid oral and topical analgesics for pain and itch; and a program going after neutrophil and immune cell biology to potentially treat fibrotic indications. Earth’s biodiversity inspires all of us at Enveda. We are committed to compliance with the Convention on Biological Diversity and the Nagoya Protocol, and to the rights of countries, local communities and indigenous peoples to their plant resources. We are dedicated to applying our research and development capabilities in a sustainable manner.